Description:

This lecture will outline and describe the current understanding of thyroid eye disease (TED) and its interrelation with Graves' Disease.  It will describe incidence, risk factors, and associated systemic signs, symptoms, and pathophysiology including Rundle's curve.  We will discuss treatment options for TED including the recent FDA approval of Teprotumumab, its clinical trials, study endpoints, and adverse reactions.  Masquerading ocular findings that may be early signs of TED will be described as well as lab testing that can help with the early detection of TED will be discussed.  Doctors have a knowledge need for this practice gap which means having the knowledge of how to detect, diagnose, and treat TED in an integrated, multidisciplinary method.

Course Code:

AOA255-SD

Speaker(s):

Jacob Lang, O.D.
drjakelang@gmail.com

Selina McGee, O.D.
drmcgee@bespokevision.org

Credits:

1

AOA Expiration Date:

4/20/2025

Related News

Constant presence: Alliance builds reputation for patient safety advocacy

Founded five years ago, the Health Care Alliance for Patient Safety (HCAPS) is making good on its mission to advocate for patient safety and protect the fundamental doctor-patient relationship. The alliance’s advocacy will be recognized with the AOA’s Apollo Award during a ceremony at the 2023 Optometry’s Meeting® June 21-24.

What defines the value of care we provide?

Health and vision plans have not adapted and grown with the care we deliver but hold back optometry’s momentum.

How to speak the universal language of care

How to create a bilingual and culturally sensitive practice, why it matters to patients and how it can set you apart from the competition.

;